Business & Finance
Champions Oncology achieves record revenue of USD5.2m for quarter
8 December 2017 -

Oncology drugs company Champions Oncology Inc (Nasdaq:CSBR) announced on Thursday its loss from operations of USD70,000 for the second fiscal second quarter ended 31 October 2017.

This reflects an improvement of 85.8% when compared to the loss from operations of USD493,000 in the second quarter of fiscal 2017.

Revenues of USD5.2m were collected for the second quarter of fiscal 2018, up 16.7% over revenues of USD4.5m for the second quarter of fiscal 2017.

Total operating expenses of USD5.3m were recorded for the second quarter fiscal 2018, a rise of 6.5% versus total operating expenses of USD5m, for the second quarter of fiscal 2017.

Login
Username:

Password: